Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$2.34
+2.6%
$1.74
$1.09
$7.67
$28.04M0.77420,334 shs26,251 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.68
+7.3%
$0.82
$0.61
$3.02
$29.81M3.04800,763 shs492,920 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$4.07
+6.5%
$4.20
$3.62
$9.18
$27.97M0.6132,599 shs57,149 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$4.73
+4.4%
$3.80
$1.75
$6.92
$7.77M1.393.90 million shs59,789 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
+2.63%+1.30%+39.29%+25.68%-65.02%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+7.31%+0.21%-3.11%-30.08%-36.02%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
+6.54%+3.04%-0.73%-7.50%-28.03%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+4.42%+6.29%+56.62%+42.47%+47.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$2.34
+2.6%
$1.74
$1.09
$7.67
$28.04M0.77420,334 shs26,251 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.68
+7.3%
$0.82
$0.61
$3.02
$29.81M3.04800,763 shs492,920 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$4.07
+6.5%
$4.20
$3.62
$9.18
$27.97M0.6132,599 shs57,149 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$4.73
+4.4%
$3.80
$1.75
$6.92
$7.77M1.393.90 million shs59,789 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
+2.63%+1.30%+39.29%+25.68%-65.02%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+7.31%+0.21%-3.11%-30.08%-36.02%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
+6.54%+3.04%-0.73%-7.50%-28.03%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+4.42%+6.29%+56.62%+42.47%+47.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
3.00
Buy$4.0070.94% Upside
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.001,227.04% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$9.00121.13% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SNOA, ITRM, KZR, and CASI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
7/16/2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$28.54M1.01N/AN/A$0.12 per share19.50
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M4.26N/AN/A$16.02 per share0.25
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.91M0.52N/AN/A$2.73 per share1.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$2.89N/AN/A-148.55%-1,844.13%-99.07%11/12/2025 (Estimated)
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.85N/AN/AN/AN/A-65.01%11/13/2025 (Estimated)
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%11/11/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$2.46N/AN/AN/A-23.87%-50.00%-16.79%11/6/2025 (Estimated)

Latest SNOA, ITRM, KZR, and CASI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/29/2025Q2 2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$0.47-$0.86-$0.39-$0.86$6.28 million$4.18 million
8/13/2025Q2 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.15-$1.87+$0.28-$1.87N/AN/A
8/7/2025Q1 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.51-$0.37+$0.14-$0.76$4.26 million$4.01 million
8/5/2025Q2 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.13-$0.16-$0.03-$0.16N/AN/A
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.48
0.68
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
2.69
2.52
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.03
7.29
7.29
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.70
1.92

Institutional Ownership

CompanyInstitutional Ownership
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.40%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
10.40%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
24.59%
CompanyEmployeesShares OutstandingFree FloatOptionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1047.17 million46.04 millionNot Optionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.32 million6.56 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.24 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$2.34 +0.06 (+2.63%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.31 -0.03 (-1.45%)
As of 09/5/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.68 +0.05 (+7.31%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$0.70 +0.02 (+3.66%)
As of 09/5/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

$4.07 +0.25 (+6.54%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$3.90 -0.17 (-4.05%)
As of 09/5/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$4.73 +0.20 (+4.42%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$4.66 -0.07 (-1.37%)
As of 09/5/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.